Literature DB >> 3307086

Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.

J T Isaacs, N Kyprianou.   

Abstract

Development of androgen-independent prostatic cancer cells from androgen-responsive cells can occur by a variety of mechanisms (e.g., environmental adaptation, multifocal origin, or genetic instability). Regardless of the mechanism of development, however, once androgen-independent cancer cells become present within prostatic cancer, the tumor is no longer homogeneous but is now heterogeneous. Once a prostatic cancer is heterogeneously composed of both androgen-dependent and -independent cancer cells, androgen withdrawal therapy, no matter how complete, cannot be curative. In order to produce cures of such heterogeneous prostatic cancers, hormonal therapy must be combined simultaneously with chemotherapy early in the course of the disease so that all the cancer populations (i.e., androgen-dependent and -independent) can be simultaneously affected within an individual patient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3307086     DOI: 10.1007/BF00254424

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  30 in total

1.  Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique.

Authors:  D P Byar; F K Mostofi
Journal:  Cancer       Date:  1972-07       Impact factor: 6.860

Review 2.  Complete androgen blockade for the treatment of prostate cancer.

Authors:  F Labrie; A Dupont; A Belanger
Journal:  Important Adv Oncol       Date:  1985

3.  Cancer incidence and mortality trends in the United States: 1935-74.

Authors:  S S Devesa; D T Silverman
Journal:  J Natl Cancer Inst       Date:  1978-03       Impact factor: 13.506

4.  Correlations between atypical primary hyperplasia and carcinoma of the prostate. A histological study of 180 total prostatectomies.

Authors:  H Kastendieck
Journal:  Pathol Res Pract       Date:  1980-11       Impact factor: 3.250

5.  Correlative histochemical and histological studies on thirty radical prostatectomy specimens.

Authors:  D Kirchheim; N R Niles; E Frankus; C V Hodges
Journal:  Cancer       Date:  1966-11       Impact factor: 6.860

6.  Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis.

Authors:  G R Prout; B Kliman; J J Daly; R A MacLaughlin; P P Griffin; H H Young
Journal:  Urology       Date:  1976-02       Impact factor: 2.649

7.  Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.

Authors:  W J Ellis; J T Isaacs
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

8.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

9.  The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer.

Authors:  J T Isaacs
Journal:  Prostate       Date:  1984       Impact factor: 4.104

10.  A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells.

Authors:  F Labrie; R Veilleux
Journal:  Prostate       Date:  1986       Impact factor: 4.104

View more
  4 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.

Authors:  Senji Hoshi; Osamu Yamaguchi; Tomoaki Fujioka; Yoichi Arai; Yoshihiko Tomita; Tomonori Habuchi; Chikara Ohyama; Tadashi Suzuki; Seiichi Orikasa
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

3.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

Review 4.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.